SANA vs. MLTX, VCEL, ACAD, XENE, MOR, SWTX, MRUS, DNLI, BHC, and ZLAB
Should you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include MoonLake Immunotherapeutics (MLTX), Vericel (VCEL), ACADIA Pharmaceuticals (ACAD), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Merus (MRUS), Denali Therapeutics (DNLI), Bausch Health Companies (BHC), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.
Sana Biotechnology vs.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment.
MoonLake Immunotherapeutics currently has a consensus target price of $84.29, indicating a potential upside of 92.39%. Sana Biotechnology has a consensus target price of $14.25, indicating a potential upside of 350.95%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics received 44 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 81.01% of users gave MoonLake Immunotherapeutics an outperform vote while only 60.61% of users gave Sana Biotechnology an outperform vote.
MoonLake Immunotherapeutics' return on equity of -15.54% beat Sana Biotechnology's return on equity.
MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 31.1% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 8 mentions for MoonLake Immunotherapeutics and 6 mentions for Sana Biotechnology. MoonLake Immunotherapeutics' average media sentiment score of 0.49 beat Sana Biotechnology's score of 0.28 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
MoonLake Immunotherapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.
Summary
MoonLake Immunotherapeutics beats Sana Biotechnology on 12 of the 16 factors compared between the two stocks.
Get Sana Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sana Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:SANA) was last updated on 1/20/2025 by MarketBeat.com Staff
